Retevmo savings card: as little as $0 a month with commercial insurance

How to pay the least

Ask for the cash price

Retevmo

We didn’t find one.

Ask your pharmacy for Retevmo’s cash price, and one or two other pharmacies too.
Retevmo’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Lilly Cares Foundation Patient Assistance Program. Note: These income limits are 300% (Group 1 Medications), 400% (Group 2 Medications), and 500% (Group 3 & 4 Medications) of 2026 Federal Poverty Guidelines. Or call 1-800-545-6962.

See if you qualify

Compare every option

Brand nameRetevmo

Authorized genericselpercatinib

Regular genericselpercatinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Retevmo?

The original

–

Brand nameThe maker’s card

Retevmo Savings Card

Savings card from Eli Lilly

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a month

The card takes up to $10,600 a year off your co-pay.

Or call 1-866-615-3716.

In the maker’s words

“Eligible commercially insured covered patients pay as little as $0 a month for Retevmo…”

From the maker’s offer on retevmo.lilly.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Retevmo itself, from the same company, sold without the brand name, and usually for less. For now Retevmo is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Non-small cell lung cancer with a RET gene fusion
Thyroid cancer with a RET gene change
Other solid tumors with a RET gene fusion

What the FDA label says

RETEVMO® is a kinase inhibitor indicated for the treatment of:

Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test
Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy
Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options

Source: the FDA label for Retevmo (Eli Lilly and Company), September 11, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/retevmo/